Benzylamines
"Benzylamines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group.
Descriptor ID |
D001596
|
MeSH Number(s) |
D02.092.200 D02.455.426.559.389.140.210
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzylamines".
Below are MeSH descriptors whose meaning is more specific than "Benzylamines".
This graph shows the total number of publications written about "Benzylamines" by people in UAMS Profiles by year, and whether "Benzylamines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2023 | 0 | 1 | 1 | 2021 | 1 | 1 | 2 | 2019 | 1 | 0 | 1 | 2014 | 0 | 1 | 1 | 2013 | 0 | 1 | 1 | 2012 | 0 | 1 | 1 | 2007 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2004 | 0 | 1 | 1 | 1991 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzylamines" by people in Profiles over the past ten years.
-
Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani M. Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 08 01; 108(8):2249-2254.
-
Hameed I, Siddiqui OM, Samad SA. MAVACAMTEN: A door that has opened in the treatment of Hypertrophic Cardiomyopathy. J Pak Med Assoc. 2023 02; 73(2):446-447.
-
Bowroju SK, Penthala NR, Lakkaniga NR, Balasubramaniam M, Ayyadevara S, Shmookler Reis RJ, Crooks PA. Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease. Bioorg Med Chem. 2021 09 01; 45:116311.
-
Johnsrud A, Ladha A, Muffly L, Shiraz P, Goldstein G, Osgood V, Shizuru JA, Johnston L, Arai S, Weng WK, Lowsky R, Rezvani AR, Meyer EH, Frank MJ, Negrin RS, Miklos DB, Sidana S. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Transplant Cell Ther. 2021 07; 27(7):590.e1-590.e8.
-
Tse K, Hammond D, Simpson D, Beynon RJ, Beamer E, Tymianski M, Salter MW, Sills GJ, Thippeswamy T. The impact of postsynaptic density 95 blocking peptide (Tat-NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate-induced epileptogenesis. J Neurosci Res. 2019 11; 97(11):1378-1392.
-
Urbano FJ, Bisagno V, Mahaffey S, Lee SH, Garcia-Rill E. Class II histone deacetylases require P/Q-type Ca2+ channels and CaMKII to maintain gamma oscillations in the pedunculopontine nucleus. Sci Rep. 2018 09 03; 8(1):13156.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|